Ado-Trastuzumab Emtansine

Introduction Overview

Generic Name

ado-trastuzumab emtansine

Brand Name

Kadcyla

Dosage Form

Intravenous infusion (Single-dose vial: 100 mg and 160 mg)

Drug Class

HER2 inhibitors

Pharmacokinetics

Absorption:
Ado-trastuzumab emtansine (Kadcyla) is administered intravenously, leading to complete bioavailability by direct entry into systemic circulation. Unlike oral agents, it bypasses gastrointestinal absorption variability. The intravenous route facilitates predictable plasma concentrations necessary for targeted therapeutic effects on HER2-positive cancer cells. Absorption data typical for monoclonal antibodies applies, with rapid attainment of peak plasma concentrations during or shortly after infusion, depending on infusion duration (generally 30 to 90 minutes).

Distribution:
Following intravenous administration, ado-trastuzumab emtansine exhibits a volume of distribution consistent with plasma and extracellular fluid, indicative of limited penetration into tissues outside the vascular and interstitial space. The drug combines trastuzumab with the cytotoxic DM1 payload; trastuzumab's distribution is primarily within the vascular compartment and interstitial spaces of tumors expressing HER2 receptors. As a large molecular weight antibody-drug conjugate (ADC), its limited penetration across tight biological barriers like the blood-brain barrier is clinically significant, impacting the potential efficacy in central nervous system metastases. Protein binding is high due to the antibody component, stabilizing systemic distribution.

Metabolism:
Ado-trastuzumab emtansine undergoes intracellular catabolism primarily within HER2-expressing tumor cells and reticuloendothelial system cells. The trastuzumab moiety targets HER2 receptors, facilitating internalization and lysosomal degradation. Inside tumor cells, the cytotoxic agent DM1 (mertansine) is released after proteolytic cleavage from the antibody. The metabolic pathways involve proteolytic enzymes, not cytochrome P450 enzymes, thus reducing direct interactions related to hepatic enzyme modulation. The systemic metabolism of free DM1, when released, follows typical hepatic pathways involving deacetylation and further biotransformation, but the amount of free DM1 in systemic circulation is minimal due to targeted delivery.

Elimination:
Clearance of ado-trastuzumab emtansine occurs mainly through proteolytic catabolism of the antibody portion in target cells and reticuloendothelial system cells. The elimination half-life is approximately 3.5 to 4 days following intravenous infusion. The conjugated drug and metabolites are eliminated primarily via biliary and hepatic pathways, with minimal renal excretion due to the large size of the molecule. Hepatic impairment can affect elimination and may increase the risk of toxicity. Clinical monitoring of liver function tests is paramount due to risks of hepatotoxicity, as impaired clearance can lead to accumulation and side effects.

Clinical implications include the need for adjusting dosing or delaying treatment in patients with significant hepatic impairment. Additionally, the pharmacokinetic profile emphasizes the importance of dosing every three weeks to maintain therapeutic plasma concentrations while minimizing toxicity. The monoclonal antibody nature of ado-trastuzumab emtansine results in nonlinear pharmacokinetics, with interpatient variability influenced by tumor burden and immune status.

Dosage Forms

Available Dosage Forms:
Kadcyla is supplied as sterile, single-dose vials for intravenous infusion in two strengths: 100 mg and 160 mg ado-trastuzumab emtansine per vial. These vials enable dosing flexibility based on patient weight calculations.

Dosages for Adults and Adolescents:
The recommended dosage for treatment of HER2-positive breast cancer is 3.6 mg/kg administered intravenously every 3 weeks (21-day cycle). The initial infusion should be given over approximately 90 minutes to monitor for infusion-related reactions. If well tolerated, subsequent infusions may be administered over approximately 30 minutes. Treatment is continued until disease progression or unacceptable toxicity occurs. Prior to initiation, patients must have confirmed HER2-positive tumor status.

Specific Patient Populations:
- Hepatic Impairment: Use caution due to increased risk of hepatotoxicity; monitoring of liver function is critical.
- Pregnant Women: Kadcyla is contraindicated due to potential fetal harm; effective contraception is required during treatment and for at least 7 months after the last dose.
- Lactating Women: Breastfeeding is contraindicated during therapy due to potential excretion in human milk.
- Pediatric Use: Safety and efficacy have not been established in children below 18 years.
- Elderly: Pharmacokinetics are not significantly altered; dose adjustments are not routinely necessary but should be individualized based on tolerance.

Dosing Considerations:
Administration requires professional healthcare setting with monitoring for infusion-related reactions. Treatment interruptions or dose delays may be required based on toxicity. No substitutions with trastuzumab are permitted, as Kadcyla combines trastuzumab with cytotoxic DM1, providing distinct pharmacologic activity.

Mechanism Of Action

Kadcyla (ado-trastuzumab emtansine) is an antibody-drug conjugate (ADC) composed of the HER2-targeted monoclonal antibody trastuzumab linked to the cytotoxic agent DM1 (mertansine). Its action involves the targeted delivery of chemotherapy specifically to cancer cells overexpressing HER2, minimizing systemic toxicity.

Upon intravenous administration, trastuzumab binds with high affinity to the extracellular domain IV of the HER2 receptor on cancer cells. This binding inhibits HER2 receptor signaling pathways involved in cellular proliferation and survival, thereby exerting a direct antitumor effect by blocking oncogenic signaling. Additionally, trastuzumab elicits immune-mediated responses including antibody-dependent cell-mediated cytotoxicity (ADCC), recruiting immune effector cells to induce apoptosis of tumor cells.

Following HER2 binding, the ADC-receptor complex undergoes receptor-mediated endocytosis, internalizing ado-trastuzumab emtansine into the tumor cell. Lysosomal degradation of trastuzumab releases the potent microtubule inhibitor DM1 within the intracellular environment. DM1 binds to tubulin, inhibiting microtubule polymerization, destabilizing the cytoskeleton. This disruption arrests the cell cycle in the G2/M phase, promoting apoptosis of the malignant cell.

Clinically, this dual-action mechanism optimizes selective cytotoxicity against HER2-positive tumors while sparing non-target tissues, thereby reducing systemic side effects common with conventional chemotherapy. Compared with trastuzumab alone, Kadcyla delivers targeted chemotherapy concurrently, improving outcomes in patients who have progressed on prior HER2 therapies. Research studies, including pivotal phase III trials, have demonstrated improved progression-free and overall survival with Kadcyla in metastatic HER2-positive breast cancer patients previously treated with trastuzumab and taxanes.

Compared to other HER2 inhibitors, Kadcyla uniquely combines targeted antibody therapy with a cytotoxic payload, distinguishing it from tyrosine kinase inhibitors and other monoclonal antibodies that do not have a conjugated chemotherapeutic component. This approach exemplifies advanced precision oncology strategies harnessing monoclonal antibodies as drug delivery vehicles for cytotoxics.

Pharmacological Actions

Selective inhibition of HER2 receptor signaling pathways by trastuzumab moiety.
Receptor-mediated endocytosis enables targeted intracellular delivery of DM1.
DM1 acts as a microtubule inhibitor, arresting cell division and inducing apoptosis in HER2-expressing tumor cells.
Antibody-dependent cellular cytotoxicity enhances immune-mediated tumor cell destruction.
Synergistic anticancer effect via combined targeted therapy and chemotherapy within a single molecule.
Reduced systemic toxicity compared to non-targeted chemotherapeutics due to selective delivery.
Delays tumor progression and growth by disrupting critical survival pathways in HER2-positive cells.
Exerts efficacy in both early and metastatic HER2-positive breast cancer as monotherapy post prior treatments.
Does not inhibit cytochrome P450 enzymes, minimizing metabolic drug interactions.
Potential for immunogenicity due to monoclonal antibody component, requiring monitoring.

Therapeutic Or Clinical Uses

Treatment of HER2-positive early-stage breast cancer following neoadjuvant therapy and surgery.
Management of HER2-positive metastatic breast cancer in patients previously treated with trastuzumab and taxane.
Second-line or later therapy for metastatic breast cancer with documented HER2-positivity and progression after prior HER2-targeted therapy.
Use as a monotherapy agent in patients with HER2-positive disease with recurrence during or within 6 months of adjuvant therapy completion.
Adjuvant therapy post chemotherapy and trastuzumab in early breast cancer to reduce recurrence risk.
Treatment option for patients intolerant or refractory to other HER2-targeted therapies.
Utility in combination with other chemotherapeutic agents is under investigation in clinical trials.
Off-label investigational use in HER2-expressing gastric and other solid tumors in clinical studies.

Side Or Adverse Effects

Infusion-related reactions including fever, chills, hypotension, and dyspnea, especially during initial infusion.
Hepatotoxicity manifesting as elevated liver enzymes, jaundice, dark urine, and right upper quadrant pain.
Hemorrhagic events such as easy bruising, nosebleeds, gastrointestinal bleeding, or hematemesis.
Cardiotoxicity including reduced left ventricular ejection fraction and congestive heart failure necessitating cardiac function monitoring.
Common adverse effects: nausea, constipation, headache, fatigue, musculoskeletal pain, and thrombocytopenia.
Peripheral neuropathy presenting as numbness, tingling, or burning sensations in extremities.
Pulmonary toxicity including cough, wheezing, dyspnea, possible interstitial lung disease.
Hypersensitivity or allergic reactions ranging from mild skin rash to anaphylaxis.
Tumor lysis syndrome symptoms such as muscle cramps, weakness, confusion, and electrolyte imbalances.
Potential for neutropenia and increased infection risk requiring hematologic monitoring.
Delayed wound healing due to anti-HER2 mechanisms inhibiting cellular proliferation.
Contraindication in pregnancy due to teratogenic and embryotoxic risks.
Elevated risk of bleeding in patients with coagulopathies or concomitant anticoagulant use.
Fatigue and malaise that may affect quality of life during prolonged treatment.
Rare cases of severe pulmonary events including pneumonitis requiring immediate medical attention.

Precautions

Perform pregnancy testing prior to initiation and enforce effective contraception during therapy and for 7 months after completion.
Monitor liver function tests prior to each dose to detect hepatotoxicity early.
Assess cardiac function (e.g., echocardiography or MUGA scan) before and during treatment to identify cardiotoxicity.
Avoid use in patients with known hypersensitivity to ado-trastuzumab emtansine or trastuzumab.
Use caution in patients with pre-existing liver disease, bleeding disorders, or pulmonary compromise.
Delay treatment if severe infusion-related reactions or uncontrolled toxicities occur until resolved.
Educate patients and caregivers on handling body fluids due to potential cytotoxicity and exposure risk for 48 hours post-infusion.
Avoid breastfeeding during treatment and for a determined period after last dose.
Be alert for signs of tumor lysis syndrome and manage electrolytes accordingly.
Monitor complete blood counts to detect thrombocytopenia or neutropenia promptly.
Consider dose modifications or treatment discontinuation for significant adverse events.
Ensure HER2 positivity is confirmed by validated testing prior to starting therapy.
Avoid concurrent use with trastuzumab or substituting Kadcyla for trastuzumab due to differing pharmacologic properties.
Avoid activities that may increase bleeding risk; apply careful wound management during treatment.
Inform patients about potential side effects and instruct on when to seek emergency care.

Warnings

Contraindicated in pregnancy due to fetal harm risk; ensure effective contraception.
Potential for severe hepatotoxicity including liver failure; monitor liver enzymes regularly.
Risk of cardiotoxicity including heart failure; requires baseline and periodic cardiac evaluation.
Infusion-related reactions can be severe; monitor patients closely during and after infusions.
Do not substitute or interchange with trastuzumab due to clinical and pharmacological differences.
May cause hemorrhagic events; caution with coadministered anticoagulants or bleeding disorders.
Exposure risk from patient body fluids; proper protective measures are required for caregivers.
Monitor for signs of pulmonary toxicity and discontinue treatment if severe respiratory symptoms develop.
Tumor lysis syndrome may occur; patients with high tumor burden require close monitoring.
Dose adjustments required in case of significant toxicity; treatment may need to be delayed or stopped.
Use in lactating women contraindicated due to unknown excretion in breast milk and potential harm.
Avoid in patients with known hypersensitivity reactions to components of ado-trastuzumab emtansine.
Patients with renal impairment should be monitored closely despite primary hepatic elimination.
Potential immunogenicity can lead to infusion reactions and affect drug efficacy.
Treatment discontinuation should be considered if severe adverse effects outweigh benefits.

Contraindication

Known hypersensitivity to ado-trastuzumab emtansine or any component of the formulation.
Pregnancy due to high risk of fetal toxicity and birth defects.
Concurrent use in patients receiving other HER2-targeted therapies like trastuzumab as substitution is not recommended.
Patients with active liver disease or significantly impaired hepatic function may be contraindicated given risk of hepatotoxicity.
Breastfeeding women during and for a recommended period after treatment due to possible excretion into milk.
Severe hypersensitivity reactions or anaphylaxis history to monoclonal antibodies may preclude use.
Uncontrolled cardiac disease or recent myocardial infarction requiring caution or contraindication.
Patients with severe bleeding diatheses until condition is adequately managed.
Those unable to comply with monitoring requirements may not be suitable candidates.
Known hypersensitivity to other ADC components or linkers if documented.

Drug Interactions

No direct cytochrome P450 enzyme interactions expected due to proteolytic metabolism of ADC component.
Concurrent use with other HER2-targeted therapies like trastuzumab may lead to overlapping toxicity; co-administration as substitution is contraindicated.
Potential for additive cardiotoxicity when used with other cardiotoxic agents such as anthracyclines.
Concomitant medications causing hepatotoxicity may increase risk of liver injury when combined with Kadcyla.
Drugs increasing bleeding risk (e.g., anticoagulants, antiplatelet agents) may enhance hemorrhagic complications.
Interactions with immunosuppressants have not been well studied; caution advised.
No significant interactions with commonly used supportive care drugs like antiemetics have been reported.
Herbal supplements with potential hepatic impact should be used cautiously during treatment.
Vaccinations during active treatment should be avoided or carefully managed due to potential immunosuppression.
No specific interaction data regarding strong CYP3A4 inhibitors or inducers since metabolism is proteolytic.
Medications affecting cardiac conduction or function may require monitoring when used concomitantly.
Avoid live vaccines during treatment because of potential immunosuppression from antibody therapy.
Body fluid exposure risk to caregivers mandates caution if coadministered with hazardous drugs.
No known interaction with hormonal therapies but clinical monitoring recommended.

Preparations Of The Drug

Single-dose vial containing 100 mg ado-trastuzumab emtansine for intravenous infusion.
Single-dose vial containing 160 mg ado-trastuzumab emtansine for intravenous infusion.
Reconstitution requires dilution in appropriate infusion fluid as per prescribing information.
Prepared infusion solution must be administered via intravenous route under healthcare professional supervision.
Storage conditions require refrigerated temperature (2°C–8°C) and protection from light until use.
Do not freeze the vials; reconstituted solutions must be used within specified time frames to maintain stability.
Proper aseptic technique should be employed during preparation to maintain sterility.
Use protective equipment when handling due to cytotoxic potential of the drug.
No oral or other pharmaceutical preparations available; strictly intravenous administration.
Adequate labeling and documentation necessary for each prepared dose per healthcare regulations.
Discard any unused portion remaining in the vial after preparing dose.
Consult detailed prescribing and pharmaceutical compounding guidelines before preparation.
Compatible infusion fluids include 0.9% sodium chloride solution or 5% dextrose solution.
Infusion sets must be used as per manufacturer recommendations to avoid adsorption of drug.
Preparation must be performed by trained personnel familiar with monoclonal antibody conjugate handling.